Efficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumonia

Basit Öğe Kaydı
dc.authoridIN, ERDAL/0000-0002-8807-5853
dc.authorwosidTelo, Selda/V-5992-2018
dc.authorwosidKuluöztürk, Mutlu/X-8228-2018
dc.contributor.authorKuluozturk, Mutlu
dc.contributor.authorIn, Erdal
dc.contributor.authorTelo, Selda
dc.contributor.authorKarabulut, Ercan
dc.contributor.authorGeckil, Aysegul Altintop
dc.date.accessioned2024-08-04T20:58:38Z
dc.date.available2024-08-04T20:58:38Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe clinical symptoms of community-acquired pneumonia (CAP) and coronavirus disease 2019 (COVID-19)-associated pneumonia are similar. Effective predictive markers are needed to differentiate COVID-19 pneumonia from CAP in the current pandemic conditions. Copeptin, a 39-aminoacid glycopeptide, is a C-terminal part of the precursor pre-provasopressin (pre-proAVP). The activation of the AVP system stimulates copeptin secretion in equimolar amounts with AVP. This study aims to determine serum copeptin levels in patients with CAP and COVID-19 pneumonia and to analyze the power of copeptin in predicting COVID-19 pneumonia. The study consists of 98 patients with COVID-19 and 44 patients with CAP. The basic demographic and clinical data of all patients were recorded, and blood samples were collected. The receiver operating characteristic (ROC) curve was generated and the area under the ROC curve (AUC) was measured to evaluate the discriminative ability. Serum copeptin levels were significantly higher in COVID-19 patients compared to CAP patients (10.2 +/- 4.4 ng/ml and 7.1 +/- 3.1 ng/ml; p < .001). Serum copeptin levels were positively correlated with leukocyte, neutrophil, and platelet count (r = -.21, p = .012; r = -.21, p = .013; r = -.20, p = .018; respectively). The multivariable logistic regression analysis revealed that increased copeptin (odds ratio [OR] = 1.183, 95% confidence interval [CI], 1.033-1.354; p = .015) and CK-MB (OR = 1.052, 95% CI, 1.013-1.092; p = .008) levels and decreased leukocyte count (OR = 0.829, 95% CI, 0.730-0.940; p = .004) were independent predictors of COVID-19 pneumonia. A cut-off value of 6.83 ng/ml for copeptin predicted COVID-19 with a sensitivity of 78% and a specificity of 73% (AUC: 0.764% 95 Cl: 0.671-0.856, p < .001). Copeptin could be a promising and useful biomarker to be used to distinguish COVID-19 patients from CAP patients.en_US
dc.identifier.doi10.1002/jmv.26870
dc.identifier.endpage3121en_US
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.issue5en_US
dc.identifier.pmid33570194en_US
dc.identifier.startpage3113en_US
dc.identifier.urihttps://doi.org/10.1002/jmv.26870
dc.identifier.urihttps://hdl.handle.net/11616/103024
dc.identifier.volume93en_US
dc.identifier.wosWOS:000618820800001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbiochemical analysisen_US
dc.subjectcoronavirusen_US
dc.subjectpathogenesisen_US
dc.subjectresearch and analysis methodsen_US
dc.subjectrespiratory tracten_US
dc.subjectSARS coronavirusen_US
dc.subjectvirus classificationen_US
dc.titleEfficacy of copeptin in distinguishing COVID-19 pneumonia from community-acquired pneumoniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu